adalimumab vs adalimumab-adbm (Cyltezo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00055497 · Phase 3 · completed
Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.
Next expected readout: June 2027 · NCT06045754 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)
Result source: NCT02499783
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02871635 · Phase 3 · completed
This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.
Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.
Reported efficacy
Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)
Result source: NCT02871635
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | adalimumab-adbm (Cyltezo) |
|---|---|---|
| Clinical remission (induction) | 37.3% vs 6.8%+30.5 vs placeboNCT024997831 other result
| —Not reported |
| Endoscopic response (induction) | —Trial running · NCT05040464 | —Not reported |
| Clinical remission (maintenance) | 38.1% vs 9.1%+29 vs placeboNCT0044543211 other results
| 68.6% vs 76.2%vs Humira EUNCT02871635 |
| Endoscopic response (maintenance) | —Trial running · NCT05040464 | —Not reported |
Clinical remission (induction)
- adalimumab
- 37.3% vs 6.8%+30.5 vs placeboNCT02499783
1 other result
- 46.9% vs 27.7% NCT00348283
- adalimumab-adbm (Cyltezo)
- —Not reported
Endoscopic response (induction)
- adalimumab
- —Trial running · NCT05040464
- adalimumab-adbm (Cyltezo)
- —Not reported
Clinical remission (maintenance)
- adalimumab
- 38.1% vs 9.1%+29 vs placeboNCT00445432
11 other results
- 47.4% vs 33.3% NCT00055497
- 66.7% vs 33.3% NCT00055497
- 78.9% vs 44.4% NCT00055497
- 83.3% vs 44.4% NCT00055497
- 36.3% vs 38.9% NCT00055497
- 40.2% vs 38.9% NCT00055497
- 32.8% vs 9.2% NCT00348283
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- adalimumab-adbm (Cyltezo)
- 68.6% vs 76.2%vs Humira EUNCT02871635
Endoscopic response (maintenance)
- adalimumab
- —Trial running · NCT05040464
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab | adalimumab-adbm (Cyltezo) |
|---|---|---|
| Dropout rate | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results15.8%40 mg every other week NCT00055497 · Phase 3 11.1%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 40.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 48.5% NCT00195715 · Phase 3 16.9%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.4% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 6.8%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 6.8%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 21.4% NCT02185014 · Phase 3 · monotherapy 61% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 60%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 34.4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 35.7%80 mg NCT01958827 · Phase 3 · monotherapy 16.4%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 36% NCT02148718 · Phase 4 · registry result, not featured evidence 26.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 26.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 25%BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results—BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 —BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Discontinued due to AEs | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results5.3%40 mg every other week NCT00055497 · Phase 3 5.6%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 12.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 15.7% NCT00195715 · Phase 3 6%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1.5% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3.9%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 2.4%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 7.1% NCT02185014 · Phase 3 · monotherapy 8% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 21.9%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 10.7%80 mg NCT01958827 · Phase 3 · monotherapy 10.9%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination — NCT02148718 · Phase 4 · registry result, not featured evidence 20%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 20%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 5.6%BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results—BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 —BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Serious AEs | 5.3%40 mg every other weeka NCT00055497 · Phase 3 show 34 more results—40 mg every other week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 0%40 mg every week NCT00055497 · Phase 3 16.7%40 mg NCT00055497 · Phase 3 2%160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 38.1% NCT00195715 · Phase 3 —40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.8% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.5%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 4.9%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy 4.6%Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy 6.4%Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 10.7% NCT02185014 · Phase 3 · monotherapy 48% NCT00686374 · Phase 3 · monotherapy 23.7%40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20%20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 40.6%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 28.6%80 mg NCT01958827 · Phase 3 · monotherapy —40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2.3% NCT02148718 · Phase 4 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 7.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 14.3%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | —BI 695501 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 2 more results8.3%BI 695501 (Baseline - Week 24 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 2.8%BI 695501 (Week 24 - Week 46 + 10 NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
| Most frequent reported AEs | 40 mg every other weeka nasopharyngitis 26.3% (placebo 38.9%) crohn's disease aggravated 21.1% (placebo 27.8%) sinusitis 21.1% (placebo 5.6%) NCT00055497 · Phase 3 show 28 more results40 mg every week crohn's disease aggravated 11.1% (placebo 27.8%) dizziness (excl vertigo) 11.1% (placebo 5.6%) nasopharyngitis 11.1% (placebo 38.9%) NCT00055497 · Phase 3 40 mg crohn's disease aggravated 17.6% (placebo 27.8%) nasopharyngitis 16.7% (placebo 38.9%) headache 14% (placebo 11.1%) NCT00055497 · Phase 3 160/80 mg white blood cell count decreased 5.9% (placebo 1%) cough 4.9% (placebo 0%) dizziness 3.9% (placebo 0%) NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg every other week or every week headache 18.9% nasopharyngitis 14.4% arthralgia 7.6% NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 crohn's disease 23.4% (placebo 29.2%) headache 14.1% (placebo 9.2%) nasopharyngitis 14.1% (placebo 12.3%) NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 viral upper respiratory tract infection 39% headache 37% upper respiratory tract infection 31% NCT00686374 · Phase 3 · monotherapy 40 mg or 20 mg every other week headache 17.2% crohn's disease 11.8% nausea 10.8% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20 mg or 10 mg every other week headache 21.1% crohn's disease 15.8% nasopharyngitis 11.6% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg Eow nasopharyngitis 56% (placebo 12%) rhinorrhoea 16% (placebo 0%) adverse drug reaction 12% (placebo 4%) NCT00445432 · Phase 2/3 · monotherapy 40 mg Eow nasopharyngitis 71.9% (placebo 12%) adverse drug reaction 18.8% (placebo 4%) iron deficiency anaemia 18.8% (placebo 0%) NCT00445432 · Phase 2/3 · monotherapy 160 mg/80 mg + 40/40 mg adverse drug reaction 11.1% (placebo 4.3%) application site swelling 11.1% (placebo 0%) blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 160 mg/80 mg headache 9.1% (placebo 4.3%) upper respiratory tract infection 9.1% (placebo 4.3%) abdominal distension 6.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80/40 mg + 40/40 mg headache 16.7% (placebo 4.3%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 4.3%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80 mg/40 mg injection site reaction 8.8% (placebo 8.7%) malaise 8.8% (placebo 0%) rhinorrhoea 8.8% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 40 mg every other week crohn's disease 16.1% abdominal pain 7.6% injection site reaction 7.6% NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) arthralgia 18.2% crohn's disease 16.4% nasopharyngitis 10.9% NCT02764762 · Phase 4 · registry result, not featured evidence · combination vomiting 7% abdominal mass 5.8% arthralgia 4.7% NCT02148718 · Phase 4 · registry result, not featured evidence Low Induction Dose leukopenia 20% pyrexia 13.3% arthralgia 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Low Induction Dose leukopenia 15.4% animal bite 7.7% aphthous stomatitis 7.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose alanine aminotransferase increased 13.3% aspartate aminotransferase increased 13.3% abdominal pain 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose mycobacterium tuberculosis complex test positive 14.3% aspartate aminotransferase increased 7.1% asthenia 7.1% NCT02015793 · Phase 2 · registry result, not featured evidence | arthralgia 8.3% respiratory tract infection 6.9% crohn's disease 5.6% NCT02871635 · Phase 3 · Crohn's Disease · phase 3 show 1 more resultnasopharyngitis 6.9% weight increased 4.2% arthralgia 2.8% NCT02871635 · Phase 3 · Crohn's Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 80 more results
show 11 more results
show 11 more results
show 6 more results
show 1 more result
show 4 more results
+ 61 further endpoints in the CSV export.
adalimumab-adbm (Cyltezo)
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00385736 · Phase 3 · completed
Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.
Next expected readout: September 2027 · NCT06257875 (registry estimate)
Reported efficacy
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)
Result source: NCT00408629
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | adalimumab-adbm (Cyltezo) |
|---|---|---|
| Clinical remission (induction) | 10% vs 11.5%−1.5 vs placeboNCT008530996 other results
| —Not reported |
| Clinical remission (maintenance) | 20% vs 7.3%+12.7 vs placeboNCT0085309914 other results
| —Not reported |
| Clinical response (induction) | 50% vs 35.4%+14.6 vs placeboNCT008530994 other results
| —Not reported |
| Endoscopic improvement (induction) | 44.4% vs 30.2%+14.2 vs placeboNCT008530992 other results
| —Not reported |
| Corticosteroid-free remission (maintenance) | 13.3% vs 5.7%+7.6 vs placeboNCT004086295 other results
| —Not reported |
Clinical remission (induction)
- adalimumab
- 10% vs 11.5%−1.5 vs placeboNCT00853099
6 other results
- 13.8% vs 11.5% NCT00853099
- 10% vs 9.2% NCT00385736
- 18.5% vs 9.2% NCT00385736
- 16.5% vs 9.3% NCT00408629
- 10% vs 11.5% NCT00853099
- 13.8% vs 11.5% NCT00853099
- adalimumab-adbm (Cyltezo)
- —Not reported
Clinical remission (maintenance)
- adalimumab
- 20% vs 7.3%+12.7 vs placeboNCT00853099
14 other results
- 26.4% vs 7.3% NCT00853099
- 17.3% vs 8.5% NCT00408629
- 29% vs 33.3% NCT02065557
- 45.2% vs 33.3% NCT02065557
- 27.3% vs 33.3% NCT02065557
- 42.9% vs 33.3% NCT02065557
- 20% vs 7.3% NCT00853099
- 17.8% vs 8.3% NCT00853099
- 26.4% vs 7.3% NCT00853099
- 17.2% vs 8.3% NCT00853099
- 42.9% vs 37.5% NCT02065557
- 45.5% vs 37.5% NCT02065557
- 42.9% vs 37.5% NCT02065557
- 44% vs 37.5% NCT02065557
- adalimumab-adbm (Cyltezo)
- —Not reported
Clinical response (induction)
- adalimumab
- 50% vs 35.4%+14.6 vs placeboNCT00853099
4 other results
- 42.5% vs 35.4% NCT00853099
- 54.6% vs 44.6% NCT00385736
- 51.5% vs 44.6% NCT00385736
- 50.4% vs 34.6% NCT00408629
- adalimumab-adbm (Cyltezo)
- —Not reported
Endoscopic improvement (induction)
- adalimumab
- 44.4% vs 30.2%+14.2 vs placeboNCT00853099
2 other results
- 39.1% vs 30.2% NCT00853099
- 41.1% vs 31.7% NCT00408629
- adalimumab-adbm (Cyltezo)
- —Not reported
Corticosteroid-free remission (maintenance)
- adalimumab
- 13.3% vs 5.7%+7.6 vs placeboNCT00408629
5 other results
- 13.3% vs 5.7% NCT00408629
- 30.8% vs 40% NCT02065557
- 31.3% vs 40% NCT02065557
- 26.7% vs 40% NCT02065557
- 35.3% vs 40% NCT02065557
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-adbm (Cyltezo): no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | 6.9%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 34.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Discontinued due to AEs | 3.1%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 14.3%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Serious AEs | 4%160/80/40a NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · monotherapy 7.8%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 11.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.5% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
| Most frequent reported AEs | 160/80/40a colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · monotherapy 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 6 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 14 more results
show 8 more results
show 2 more results
+ 51 further endpoints in the CSV export.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195676 · Phase 3 · completed
Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.
Next expected readout: April 2028 · NCT07529925 (registry estimate)
Reported efficacy
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)
Result source: NCT00195676
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT03210259 · Phase 3 · completed
After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | adalimumab-adbm (Cyltezo) |
|---|---|---|
| PASI 75 | 77.8% vs 11.5%+66.3 vs placeboNCT016460737 other results
| —Not reported |
| PASI 90 | 61.8% vs 54.2%vs EU RPPNCT025813453 other results
| —Not reported |
| PASI 100 | 18.4% vs 2.7%vs MethotrexateNCT012516142 other results
| —Not reported |
| sPGA 0/1 | 60.5% vs 40.5%vs MethotrexateNCT0125161411 other results
| —Not reported |
| DLQI, change | -4.8 vs -4.2−0.6 vs placeboNCT007357873 other results
| —Not reported |
PASI 75
- adalimumab
- 77.8% vs 11.5%+66.3 vs placeboNCT01646073
7 other results
- 80.1% vs 79% NCT02581345
- 57.9% vs 32.4% NCT01251614
- 43.6% vs 32.4% NCT01251614
- 45.3% vs 2.3% NCT01646073
- 9.8% vs 0% NCT01646073
- 30.6% vs 8.7% NCT00735787
- 67% vs 27% NCT00932113
- adalimumab-adbm (Cyltezo)
- —Not reported
PASI 90
- adalimumab
- 61.8% vs 54.2%vs EU RPPNCT02581345
3 other results
- 28.9% vs 21.6% NCT01251614
- 30.8% vs 21.6% NCT01251614
- 20.4% vs 0% NCT00735787
- adalimumab-adbm (Cyltezo)
- —Not reported
PASI 100
- adalimumab
- 18.4% vs 2.7%vs MethotrexateNCT01251614
2 other results
- 10.3% vs 2.7% NCT01251614
- 14.3% vs 0% NCT00735787
- adalimumab-adbm (Cyltezo)
- —Not reported
sPGA 0/1
- adalimumab
- 60.5% vs 40.5%vs MethotrexateNCT01251614
11 other results
- 41% vs 40.5% NCT01251614
- 80.5% vs 14.9% NCT01646073
- 57.4% vs 4.6% NCT01646073
- 20.1% vs 0% NCT01646073
- 68.9% vs 66.1% NCT02581345
- 30.6% vs 4.3% NCT00735787
- 28.6% vs 13% NCT00735787
- 24.5% vs 8.7% NCT00735787
- 20.4% vs 4.3% NCT00735787
- 8.2% vs 4.3% NCT00735787
- 73% vs 27% NCT00932113
- adalimumab-adbm (Cyltezo)
- —Not reported
DLQI, change
- adalimumab
- -4.8 vs -4.2−0.6 vs placeboNCT00735787
3 other results
- -7.9 vs -3.7 NCT01553058
- -4.1 vs -3.1 NCT00735787
- -4.3 vs -3.4 NCT00735787
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | 41.3%a NCT00195676 · Phase 3 show 35 more results6.7% NCT00932113 · Phase 4 · registry result, not featured evidence 3% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 4.7% NCT01265823 · Phase 4 · registry result, not featured evidence 16.3% NCT00735787 · Phase 4 · registry result, not featured evidence 9.4% NCT05637515 · Phase 3 · registry result, not featured evidence 50% NCT02533375 · Phase 3 · registry result, not featured evidence 5.2%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 13.8%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 21.1%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 33.3%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 1.5%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 11%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 17.2%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 2%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 2.9%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 7.7%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 7.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence 11.8%40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 22.4%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 24.7%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 11.1% NCT01320293 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 5.6%a NCT00195676 · Phase 3 show 35 more results— NCT00932113 · Phase 4 · registry result, not featured evidence — NCT01553058 · Phase 4 · registry result, not featured evidence — NCT01644396 · Phase 4 · registry result, not featured evidence — NCT01265823 · Phase 4 · registry result, not featured evidence — NCT00735787 · Phase 4 · registry result, not featured evidence — NCT05637515 · Phase 3 · registry result, not featured evidence 20% NCT02533375 · Phase 3 · registry result, not featured evidence 1%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 4.6%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 2.6%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0.6%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 6.9%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —Group A NCT00927069 · Phase 3 · registry result, not featured evidence —Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.9%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 1.6%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence —80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence —40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence — NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence |
| Serious AEs | 12.9%a NCT00195676 · Phase 3 show 35 more results0% NCT00932113 · Phase 4 · registry result, not featured evidence 6.1% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 0.7% NCT01265823 · Phase 4 · registry result, not featured evidence 4.1% NCT00735787 · Phase 4 · registry result, not featured evidence 1.7% NCT05637515 · Phase 3 · registry result, not featured evidence 30% NCT02533375 · Phase 3 · registry result, not featured evidence —Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 1.4%Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 3.7%Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 7.3%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 3.2%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 5.7%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 7.7%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 1.2%Eow NCT01646073 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 3.4%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.4%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 4.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 19%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 21.3%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | show 29 more resultsupper respiratory tract infection 40% dizziness 13.3% flu-like symptoms 13.3% NCT00932113 · Phase 4 · registry result, not featured evidence upper respiratory infection 9.1% (placebo 12.9%) joint range of motion decrease 6.1% (placebo 0%) headache 3% (placebo 6.5%) NCT01553058 · Phase 4 · registry result, not featured evidence latent tuberculosis 8% rhinitis 6% alanine aminotransferase increased 2% NCT01644396 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 11.3% hyperglycemia 10.7% arthralgia 6.7% NCT01265823 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.5% (placebo 13%) headache 14.3% (placebo 4.3%) cough 8.2% (placebo 4.3%) NCT00735787 · Phase 4 · registry result, not featured evidence headache 2.2% nasopharyngitis 2.2% upper respiratory tract infection 2.2% NCT05637515 · Phase 3 · registry result, not featured evidence nasopharyngitis 30% pruritus 30% hypoalbuminaemia 20% NCT02533375 · Phase 3 · registry result, not featured evidence injection site reaction 23.9% nasopharyngitis 6.7% headache 3.2% NCT02581345 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% psoriasis 10.3% injection site reaction 10% NCT02581345 · Phase 3 · registry result, not featured evidence EOW upper respiratory tract infection 8.3% (placebo 8.3%) headache 5.5% (placebo 0%) nasopharyngitis 5.5% (placebo 9.3%) NCT02016482 · Phase 3 · registry result, not featured evidence EOW nasopharyngitis 12.8% (placebo 9.3%) upper respiratory tract infection 4.3% (placebo 8.3%) depression 3.2% (placebo 0.9%) NCT02016482 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 21.1% headache 15.8% dry skin 7.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 18.5% back pain 11.1% headache 11.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 28.7% headache 25.3% upper respiratory tract infection 14.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 25.6% headache 17.9% cough 10.3% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg cough 18.2% decreased appetite 9.1% gastroenteritis 9.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 23.1% agitation 7.7% cough 7.7% NCT01251614 · Phase 3 · registry result, not featured evidence Eow upper respiratory tract infection 10.1% (placebo 6.9%) oropharyngeal pain 4.1% (placebo 1.1%) nasopharyngitis 3.8% (placebo 5.7%) NCT01646073 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% cough 3.7% headache 3.7% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.2% injection site erythema 7.3% nasopharyngitis 7.3% NCT00566722 · Phase 3 · registry result, not featured evidence fatigue 6.9% pharyngitis 6.9% abdominal pain 3.4% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18% back pain 8% common cold 8% NCT00927069 · Phase 3 · registry result, not featured evidence headache 11.4% common cold 5.7% upper respiratory tract infection 5.7% NCT00927069 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.7% headache 5.2% psoriasis 5.2% NCT00574249 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.3% headache 6% pruritus 5.8% NCT00574249 · Phase 3 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.8% upper respiratory tract infection 10.8% headache 4.9% NCT00513370 · Phase 3 · registry result, not featured evidence 80 mg every other week nasopharyngitis 77.6% blood triglycerides increased 29.3% blood creatine phosphokinase increased 25.9% NCT00647400 · Phase 2/3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 75.3% blood triglycerides increased 24.7% alanine aminotransferase increased 23.6% NCT00647400 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 22.2% elbow strain 5.6% heartburn 5.6% NCT01320293 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 27 more results
show 39 more results
show 9 more results
show 16 more results
show 5 more results
+ 181 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195702 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).
Next expected readout: December 2027 · NCT06440629 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)
Result source: NCT00195702
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | adalimumab-adbm (Cyltezo) |
|---|---|---|
| ACR20 | 63.3% vs 29.5%+33.8 vs placeboNCT0019570228 other results
| —Not reported |
| ACR50 | 41.2% vs 45.9%vs MethotrexateNCT0019566319 other results
| —Not reported |
| ACR70 | 47.4% vs 22.7%+24.7 vs placeboNCT0087046716 other results
| —Not reported |
| DAS28-CRP remission | 38.5% vs 42.9%vs Standard of CareNCT011624215 other results
| —Not reported |
| HAQ-DI, change | -0.6 vs -0.3−0.3 vs placeboNCT0019570222 other results
| —Not reported |
| Modified Sharp score, change | 0.1 vs 2.7−2.6 vs placeboNCT0019570215 other results
| —Not reported |
ACR20
- adalimumab
- 63.3% vs 29.5%+33.8 vs placeboNCT00195702
28 other results
- 50.3% vs 33.9% NCT00647270
- 57% vs 35% NCT00538902
- 47.3% vs 33.9% NCT00647270
- 51.2% vs 35% NCT00538902
- 60.8% vs 29.5% NCT00195702
- 58.9% vs 24% NCT00195702
- 54.7% vs 24% NCT00195702
- 75.4% vs 56.4% NCT00870467
- 49.3% vs 56% NCT00195663
- 69.4% vs 56% NCT00195663
- 50% vs 59.9% NCT00195663
- 69% vs 59.9% NCT00195663
- 54.4% vs 62.6% NCT00195663
- 72.8% vs 62.6% NCT00195663
- 53.3% vs 61.5% NCT00195663
- 68.7% vs 61.5% NCT00195663
- 69.2% vs 71.4% NCT01500278
- 84.8% vs 80.4% NCT00420927
- 66.4% vs 80.4% NCT00420927
- 64.5% vs 60.8% NCT01500278
- 68% vs 68% NCT01712178
- 62% vs 68% NCT01712178
- 46.2% vs 65.7% NCT01162421
- 51.3% vs 65.7% NCT01162421
- 56.4% vs 68.6% NCT01162421
- 66.7% vs 60% NCT01162421
- 64.1% vs 37.1% NCT01162421
- 69.2% vs 57.1% NCT01162421
- adalimumab-adbm (Cyltezo)
- —Not reported
ACR50
- adalimumab
- 41.2% vs 45.9%vs MethotrexateNCT00195663
19 other results
- 61.6% vs 45.9% NCT00195663
- 64.3% vs 38.7% NCT00870467
- 36.9% vs 42.8% NCT00195663
- 59% vs 42.8% NCT00195663
- 41.6% vs 44.4% NCT00195663
- 60.1% vs 44.4% NCT00195663
- 35% vs 40.5% NCT00195663
- 58.6% vs 40.5% NCT00195663
- 78.1% vs 69.6% NCT00420927
- 46.3% vs 69.6% NCT00420927
- 48% vs 50% NCT01712178
- 36% vs 40% NCT01712178
- 33.3% vs 42.9% NCT01162421
- 38.5% vs 45.7% NCT01162421
- 43.6% vs 34.3% NCT01162421
- 48.7% vs 40% NCT01162421
- 43.6% vs 22.9% NCT01162421
- 38.5% vs 22.9% NCT01162421
- 64.7% vs 51.6% NCT03823391
- adalimumab-adbm (Cyltezo)
- —Not reported
ACR70
- adalimumab
- 47.4% vs 22.7%+24.7 vs placeboNCT00870467
16 other results
- 28.1% vs 28.4% NCT00195663
- 46.6% vs 28.4% NCT00195663
- 28.8% vs 29.2% NCT00195663
- 47.4% vs 29.2% NCT00195663
- 25.9% vs 27.2% NCT00195663
- 45.5% vs 27.2% NCT00195663
- 19.7% vs 22.2% NCT00195663
- 42.5% vs 22.2% NCT00195663
- 69.5% vs 57.1% NCT00420927
- 30.1% vs 57.1% NCT00420927
- 23.1% vs 40% NCT01162421
- 30.8% vs 20% NCT01162421
- 30.8% vs 14.3% NCT01162421
- 25.6% vs 22.9% NCT01162421
- 28.2% vs 8.6% NCT01162421
- 15.4% vs 2.9% NCT01162421
- adalimumab-adbm (Cyltezo)
- —Not reported
DAS28-CRP remission
- adalimumab
- 38.5% vs 42.9%vs Standard of CareNCT01162421
5 other results
- 30.8% vs 34.3% NCT01162421
- 35.9% vs 22.9% NCT01162421
- 28.2% vs 31.4% NCT01162421
- 35.9% vs 11.4% NCT01162421
- 17.9% vs 8.6% NCT01162421
- adalimumab-adbm (Cyltezo)
- —Not reported
HAQ-DI, change
- adalimumab
- -0.6 vs -0.3−0.3 vs placeboNCT00195702
22 other results
- -0.6 vs -0.3 NCT00195702
- -0.6 vs -0.2 NCT00195702
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.3 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.5 vs -0.3 NCT00538902
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.4 vs -0.3 NCT00538902
- -0.6 vs -0.2 NCT00195702
- -0.8 vs -0.8 NCT00195663
- -1.1 vs -0.8 NCT00195663
- -0.6 vs -0.7 NCT01500278
- -0.5 vs -0.6 NCT01162421
- -0.6 vs -0.6 NCT01162421
- -0.5 vs -0.6 NCT01162421
- -0.5 vs -0.5 NCT01162421
- -0.5 vs -0.3 NCT01162421
- -0.4 vs -0.4 NCT01162421
- adalimumab-adbm (Cyltezo)
- —Not reported
Modified Sharp score, change
- adalimumab
- 0.1 vs 2.7−2.6 vs placeboNCT00195702
15 other results
- 0.8 vs 2.7 NCT00195702
- 1.5 vs 2.4 NCT00870467
- 3 vs 5.7 NCT00195663
- 1.3 vs 5.7 NCT00195663
- 0.7 vs 6.2 NCT00195702
- 0.1 vs 4.8 NCT00195702
- 0.3 vs 1.3 NCT00195702
- 2.6 vs 6.2 NCT00195702
- 1.2 vs 4.8 NCT00195702
- 0.6 vs 1.3 NCT00195702
- 5.5 vs 10.4 NCT00195663
- 1.9 vs 10.4 NCT00195663
- 0.0 vs 2.2 NCT01162421
- 0.2 vs 1.6 NCT01162421
- 0.0 vs 0.9 NCT01162421
- adalimumab-adbm (Cyltezo)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · adalimumab-adbm (Cyltezo): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | 23.2%40 mg every other weeka NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 20.8%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 24.8%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 32.5% NCT01162421 · Phase 4 · registry result, not featured evidence 10.3%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 12.3%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 9.2%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 6.1%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 7%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 15.3%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 39.4%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 26.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 36% NCT00690573 · Phase 3 · registry result, not featured evidence 9.4%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 62.1% NCT00195650 · Phase 3 · registry result, not featured evidence 5%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 8.2%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 11.2%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 47.6%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 4.1%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 2%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 9.1%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 64%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weeka NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 —20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 1.3%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.5% NCT01162421 · Phase 4 · registry result, not featured evidence 3.9%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 4.5%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 3.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 0%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 9.9%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 11.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination — NCT00690573 · Phase 3 · registry result, not featured evidence —DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 22.9% NCT00195650 · Phase 3 · registry result, not featured evidence 3%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 4.4%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 11%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 0%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 13%40 mg every other weeka NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 16%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 7.4%maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 4.5%reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 2.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 7.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 1%Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 10.3% NCT01162421 · Phase 4 · registry result, not featured evidence 7.1%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 3.9%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 11.4%ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 6.9%ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 7.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 23.7%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 20.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 24% NCT00690573 · Phase 3 · registry result, not featured evidence 4.1%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 51.1% NCT00195650 · Phase 3 · registry result, not featured evidence 1%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 4.9%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.3%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 6.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 1.9%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 35.9%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence —40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 12.5%Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 2.3%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 4.5%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 0%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence 0%Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 0%New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 40%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weeka injection site pain 17.9% (placebo 21.5%) upper respiratory tract infection 16.9% (placebo 11%) headache 11.6% (placebo 5%) NCT00195702 · Phase 3 show 40 more results20 mg weekly injection site pain 17.5% (placebo 21.5%) upper respiratory tract infection 16.5% (placebo 11%) headache 13.2% (placebo 5%) NCT00195702 · Phase 3 maximum tolerated dose liver function test abnormal 8.8% abdominal pain upper 2.9% dry mouth 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination reduced dose dry mouth 3% alanine aminotransferase increased 1.5% cough 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination 40 mg Eow cough 2.7% (placebo 5%) nasopharyngitis 2.7% (placebo 20%) urinary tract infection 1.4% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.3% (placebo 20%) upper respiratory tract infection 7.7% (placebo 0%) hepatic enzyme increased 5.1% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 20%) arthralgia 5.9% (placebo 0%) influenza 4.9% (placebo 10%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 25.6% nasopharyngitis 20.5% alanine aminotransferase increased 15.4% NCT01162421 · Phase 4 · registry result, not featured evidence high dose nausea 10.3% upper respiratory tract infection 7.7% urinary tract infection 7.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination low dose nausea 9.7% fatigue 9.1% upper respiratory tract infection 9.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination cough 6.7% (placebo 3.6%) influenza 5.7% (placebo 2.7%) nasopharyngitis 5.7% (placebo 3.6%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 11.2% (placebo 6.3%) nasopharyngitis 8.9% (placebo 3.6%) alanine aminotransferase increased 6.2% (placebo 2.7%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination injection site reaction 8.8% headache 5.9% nausea 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 20 mg MTX nasopharyngitis 11.2% headache 9.2% alopecia 8.2% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 10 mg MTX nausea 13.1% alopecia 6.1% diarrhoea 6.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5 mg MTX diarrhoea 6% headache 6% nasopharyngitis 6% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2.5 mg MTX nausea 7.1% arthralgia 6.1% abdominal pain upper 4.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 22.6% headache 21.5% nausea 17.5% NCT00195663 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.2% headache 20.5% upper respiratory tract infection 18.7% NCT00195663 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 56% upper respiratory tract infection 56% influenza 32% NCT00690573 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.2% (placebo 16.6%) hepatic function abnormal 8.2% (placebo 5.5%) alanine aminotransferase increased 7.6% (placebo 3.7%) NCT00870467 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 46.3% rheumatoid arthritis 25.4% sinusitis 24.9% NCT00195650 · Phase 3 · registry result, not featured evidence 40 mg/0.8 mL nasopharyngitis 4% respiratory disorder 4% headache 3% NCT01231321 · Phase 3 · registry result, not featured evidence 40 mg every other week nausea 5.5% (placebo 5.3%) headache 4.9% (placebo 5.3%) nasopharyngitis 4.9% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 6.6% (placebo 5.3%) upper respiratory tract infection 2.6% (placebo 7%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly upper respiratory tract infection 3.2% (placebo 7%) nasopharyngitis 2.7% (placebo 5.3%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly nausea 6.2% (placebo 5.3%) upper respiratory tract infection 5.2% (placebo 7%) headache 4.7% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg or 80 mg every other week nasopharyngitis 60.2% adverse drug reaction 29.5% antinuclear antibody positive 15.9% NCT00603993 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 45% adverse drug reaction 23.6% dna antibody positive 16.2% NCT00235872 · Phase 3 · registry result, not featured evidence 40 mg EOW upper respiratory tract infection 14% (placebo 11.7%) injection site pruritus 5.8% (placebo 0%) nasopharyngitis 5.8% (placebo 6.7%) NCT00538902 · Phase 2/3 · registry result, not featured evidence 80 mg EOW upper respiratory tract infection 12.4% (placebo 11.7%) nasopharyngitis 7.4% (placebo 6.7%) injection site pruritus 4.1% (placebo 0%) NCT00538902 · Phase 2/3 · registry result, not featured evidence urinary tract infection 11.8% abdominal discomfort 5.9% arthralgia 5.9% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 12.5% bronchitis 6.3% drug hypersensitivity 6.3% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.9% rheumatoid arthritis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.6% cystitis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence 40 mg every other week nasopharyngitis 10% cystitis 8% nausea 8% NCT01712178 · Phase 2 · registry result, not featured evidence pharyngitis 1.6% rash erythematous 1.6% protein urine present 0% NCT01561313 · Phase 2 · registry result, not featured evidence protein urine present 1.6% pharyngitis 0% rash erythematous 0% NCT01561313 · Phase 2 · registry result, not featured evidence 40 mg Eow nasopharyngitis 60% diarrhoea 24% pruritus 20% NCT00235833 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 28 more results
show 15 more results
show 22 more results
show 1 more result
show 1 more result
show 7 more results
show 13 more results
show 15 more results
show 11 more results
show 1 more result
show 1 more result
+ 236 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · adalimumab-adbm (Cyltezo)'s landscape